In recent years, the need for more precise and efficient therapy of CSC has increased—CSC vaccines for OC (targeting CD117+CD44+ OCSC) were able to activate immune responses to autologous tumor antigens, which in turn reduced OCSC, prolonged survival, and reduced tumor growth in mice [464]. Here, KIT is linked to neoplasm.